表紙
市場調查報告書

再生醫療的全球市場 至2024年的預測:各種類 (細胞為基礎的免疫療法、細胞療法 (同種異體細胞/自我細胞產品),再生醫療,基因治療)、用途、地區

Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024

出版商 MarketsandMarkets 商品編碼 363089
出版日期 內容資訊 英文 108 Pages
訂單完成後即時交付
價格
Back to Top
再生醫療的全球市場 至2024年的預測:各種類 (細胞為基礎的免疫療法、細胞療法 (同種異體細胞/自我細胞產品),再生醫療,基因治療)、用途、地區 Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024
出版日期: 2019年03月29日內容資訊: 英文 108 Pages
簡介

全球再生醫療市場預計在2019年達133億美元,2024年達387億美元,並以23.8%的年複合成長率 (CAGR) 成長。市場成長的主要原因,是世界各國的癌症患者的增加和人口高齡化,轉移到再生醫療的動向 (CAR-T細胞等),醫療費的增加和可支配所得的上升等。各用途中,肌肉骨骼系統疾病需求佔最大的佔有率,另一方面癌症治療 (腫瘤) 需求今後預計將急速成長。

本報告提供全球再生醫療市場相關調查分析,市場概要,產業趨勢,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 簡介
  • 市場動態
    • 促進因素
      • 慢性疾病、遺傳基因疾病的患病人數的增加
      • 再生醫療研究的政府投資的擴大
      • 再生醫療產品的認證數量、開發中產品的增加
    • 阻礙因素
      • 在ES細胞的研究階段的利用相關道德疑慮
    • 市場機會
      • 美國「21世紀醫療法 (21st century cures act)」的實施
      • 器官移植的需求增加

第6章 再生醫療市場:各類型

  • 簡介
  • 細胞為基礎的免疫療法、細胞療法產品
    • 同種異體細胞產品
    • 自我細胞產品
  • 再生醫療產品
  • 細胞療法產品

第7章 再生醫療市場:各用途

  • 簡介
  • 肌肉骨骼系統疾病
  • 傷口護理
  • 腫瘤
  • 眼科疾病
  • 糖尿病
  • 其他

第8章 再生醫療市場:各地區

  • 簡介
  • 北美 (美國,加拿大)
  • 歐洲 (英國,德國,法國等)
  • 亞太地區 (日本,中國,澳洲等)
  • 其他國家 (RoW)

第9章 競爭環境

  • 概要
  • 市場排行榜分析
  • 主要策略
    • 產品銷售
  • 企業策略方向性:製圖
    • 供應商的選擇標準
    • 企業先驅
    • 創新的企業
    • 活動的企業
    • 新企業
  • 企業策略方向性:Start-Ups企業的情況
    • 進步企業
    • 新加入企業
    • 模仿企業
    • 活動企業

第10章 企業簡介 (概要,主要產品與服務,策略、分析師的考察,近幾年趨勢,MnM的見解)

  • NOVARTIS AG
  • VERICEL
  • INTEGRA LIFESCIENCES
  • MIMEDX GROUP
  • STRYKER
  • WRIGHT MEDICAL
  • SPARK THERAPEUTICS
  • OSIRIS THERAPEUTICS
  • KITE PHARMA (GILEAD SCIENCES的子公司)
  • ORGANOGENESIS

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 4419

"Regenerative medicine market to register a CAGR of 23.8% from 2019 to 2024"

The regenerative medicine market is projected to reach USD 38.7 billion by 2024 from USD 13.3 billion in 2019, at a CAGR of 23.8% during the forecast period. The rising global incidence of cancer, increasing global aging population, and technological shifts in regenerative medicine such as CAR-T cell therapy are factors expected to drive market growth during the forecast period. Economies with growing healthcare sector and high disposable income are also expected to provide opportunities for the growth of the market.

"Cell-based immunotherapy & cell therapy products likely to grow at a CAGR during the forecast period"

By type, the regenerative medicine market is segmented into cell-based immunotherapy & cell therapy products, tissue-engineered products, and gene therapy products. The cell-based immunotherapy & cell therapy products segment dominates this market in 2019 and is the fastest growing segment due to increasing launches of novel cell therapies, increasing demand for novel treatments with less side effects for the treatment of cancer are the major factors driving the growth of this market segment.

"Musculoskeletal Disorders application segment accounted for the largest share of the regenerative medicine market in 2019 and oncology segment expected to achive highest growth rate in the future"

By application, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, and other applications. Musculoskeletal disorder applications segment likely to account for the largest share of this market and oncology is likely to register highest CAGR during the forecast period. The surging incidence rate of orthopaedic diseases & injuries, and rising geriatric population, are the key drivers for the growth of this market segment.

"North America is expected to attain fastest growth rate and dominated the regenerative medicine market in 2019"

North America, which includes the US, & Canada, accounted for the largest share of the regenerative medicine market. The large share of this market segment can be attributed to the increasing incidence of chronic wounds, diabetes, leukemia and musculoskeletal diseases in this region.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (20%) , Tier 2 (45%), and Tier 3 (35%)
  • By Designation: C-level (30%), Director-level (20%), and Others (50%)
  • By Region: North America (35%), Europe (24%), Asia (25%), and RoW (16%)

The major players in this market are: Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US). Product launches and acquisitions are the key growth strategies followed by most players in this market.

Research Coverage:

This report studies the regenerative medicine market based on type, and region. The report also analyzes factors (such as drivers, restraints and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total regenerative medicine market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on regenerative medicines offered by the top 10 players in the regenerative medicine market. The report analyzes the regenerative medicine market by type, application, and region
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various regenerative medicine across key geographic regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the regenerative medicine market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the regenerative medicine market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 MARKETS COVERED
    • 1.2.2 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 SECONDARY DATA
    • 2.1.1 KEY DATA FROM SECONDARY SOURCES
  • 2.2 PRIMARY DATA
    • 2.2.1 KEY DATA FROM PRIMARY SOURCES
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.2 TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 REGENERATIVE MEDICINE: MARKET OVERVIEW
  • 4.2 REGENERATIVE MEDICINE MARKET, BY TYPE & APPLICATION (2019)
  • 4.3 GEOGRAPHICAL SNAPSHOT OF THE REGENERATIVE MEDICINE MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 CLINICAL TRIALS FOR REGENERATIVE MEDICINE
  • 5.3 MARKET DYNAMICS
    • 5.3.1 DRIVERS
      • 5.3.1.1 Rising prevalence of chronic diseases and genetic disorders
      • 5.3.1.2 Rising government investments in regenerative medicine research
      • 5.3.1.3 Product approvals and growing pipeline of regenerative medicine products
    • 5.3.2 RESTRAINTS
      • 5.3.2.1 Ethical concerns related to the use of embryonic stem cells in Research & Development
    • 5.3.3 OPPORTUNITIES
      • 5.3.3.1 Implementation of the 21st century cures act
      • 5.3.3.2 Rising demand for organ transplantation

6 REGENERATIVE MEDICINE MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS
    • 6.2.1 ALLOGENEIC PRODUCTS
    • 6.2.2 AUTOLOGOUS PRODUCTS
  • 6.3 TISSUE-ENGINEERED PRODUCTS
  • 6.4 GENE THERAPY PRODUCTS

7 REGENERATIVE MEDICINE MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 MUSCULOSKELETAL DISORDERS
    • 7.2.1 MUSCULOSKELETAL DISORDERS SEGMENT WILL CONTINUE TO DOMINATE THE REGENERATIVE MEDICINE MARKET IN 2024
  • 7.3 WOUND CARE
    • 7.3.1 INCREASING PREVALENCE OF TARGET CONDITIONS TO DRIVE THE GROWTH OF THIS APPLICATION SEGMENT
  • 7.4 ONCOLOGY
    • 7.4.1 INCREASING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH
  • 7.5 OCULAR DISORDERS
    • 7.5.1 GROWING NUMBER OF PRODUCT APPROVALS TO SUPPORT MARKET GROWTH
  • 7.6 DIABETES
    • 7.6.1 INCREASING INCIDENCE OF DIABETES AND THE GROWING FOCUS OF COMPANIES ON DEVELOPING REGENERATIVE MEDICINE FOR THE TREATMENT OF DIABETES ARE THE KEY FACTORS DRIVING MARKET GROWTH
  • 7.7 OTHER APPLICATIONS

8 REGENERATIVE MEDICINE MARKET, BY REGION

  • 8.1 INTRODUCTION
  • 8.2 NORTH AMERICA
    • 8.2.1 US
      • 8.2.1.1 US accounts for the largest share of the regenerative medicine market in North America
    • 8.2.2 CANADA
      • 8.2.2.1 Increasing R&D funding for regenerative medicine is a key factor influencing the growth of the Canadian regenerative medicine market
  • 8.3 EUROPE
    • 8.3.1 UK
      • 8.3.1.1 UK accounts for the largest market share in the European market
    • 8.3.2 GERMANY
      • 8.3.2.1 Germany has a strong foundation for R&D, including over 1,000 public and private institutions
    • 8.3.3 FRANCE
      • 8.3.3.1 Rising R&D expenditure, a major growth driver in France
    • 8.3.4 REST OF EUROPE
  • 8.4 ASIA PACIFIC
    • 8.4.1 JAPAN
      • 8.4.1.1 Comparatively lenient regulations and rising geriatric population will drive market growth
    • 8.4.2 CHINA
      • 8.4.2.1 Favorable investments and government support will contribute to the growth of the Chinese market
    • 8.4.3 AUSTRALIA
      • 8.4.3.1 Strong research base and availability of funds will push market growth in Australia
    • 8.4.4 ROAPAC
  • 8.5 REST OF THE WORLD

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 MARKET RANKING ANALYSIS, 2017
  • 9.3 KEY STRATEGIES
    • 9.3.1 PRODUCT LAUNCHES
  • 9.4 COMPETITIVE LEADERSHIP MAPPING (2018)
    • 9.4.1 VENDOR INCLUSION CRITERIA
    • 9.4.2 VISIONARY LEADERS
    • 9.4.3 INNOVATORS
    • 9.4.4 DYNAMIC DIFFERENTIATORS
    • 9.4.5 EMERGING COMPANIES
  • 9.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2018)
    • 9.5.1 PROGRESSIVE COMPANIES
    • 9.5.2 STARTING BLOCKS
    • 9.5.3 RESPONSIVE COMPANIES
    • 9.5.4 DYNAMIC COMPANIES

10 COMPANY PROFILES

(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 10.1 NOVARTIS AG
  • 10.2 VERICEL
  • 10.3 INTEGRA LIFESCIENCES
  • 10.4 MIMEDX GROUP
  • 10.5 STRYKER
  • 10.6 WRIGHT MEDICAL
  • 10.7 SPARK THERAPEUTICS
  • 10.8 OSIRIS THERAPEUTICS
  • 10.9 KITE PHARMA (SUBSIDIARY OF GILEAD SCIENCES)
  • 10.10 ORGANOGENESIS

Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 11.2 DISCUSSION GUIDE
  • 11.3 AVAILABLE CUSTOMIZATIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: FEW IMPORTANT CLINICAL STUDIES IN THE REGENERATIVE MEDICINE MARKET
  • TABLE 2: CANCER INCIDENCE AND MORTALITY, BY REGION, 2012-2035
  • TABLE 3: FUNDING FOR REGENERATIVE MEDICINE RESEARCH BY THE NIH UNDER THE 21ST CENTURY CURES ACT
  • TABLE 4: NIH FUNDING FOR REGENERATIVE MEDICINE RESEARCH IN THE US, 2014-2016 (USD MILLION)
  • TABLE 5: CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE FUNDING FOR REGENERATIVE MEDICINE RESEARCH
  • TABLE 6: NUMBER OF COMPANIES OPERATING IN THE REGENERATIVE MEDICINE MARKET, BY REGION (2014-2018)
  • TABLE 7: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 8: FEW OF THE COMMERCIALIZED CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS
  • TABLE 9: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 10: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 11: CELL-BASED ALLOGENEIC REGENERATIVE MEDICINE
  • TABLE 12: ALLOGENEIC PRODUCTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 13: CELL-BASED AUTOLOGOUS REGENERATIVE MEDICINE
  • TABLE 14: AUTOLOGOUS PRODUCTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 15: FEW OF THE COMMERCIALIZED TISSUE-ENGINEERED PRODUCTS
  • TABLE 16: REGENERATIVE MEDICINE MARKET FOR TISSUE-ENGINEERED PRODUCTS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 17: FEW OF THE COMMERCIALIZED GENE THERAPY PRODUCTS
  • TABLE 18: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY PRODUCTS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 19: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 20: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 21: REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR THE TREATMENT OF ACUTE & CHRONIC WOUNDS
  • TABLE 22: REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 23: NUMBER OF CANCER PATIENTS, BY TYPE, 2012-2030
  • TABLE 24: INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL-BASED IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER
  • TABLE 25: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 26: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 27: REGENERATIVE MEDICINE MARKET FOR DIABETES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 28: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 29: REGENERATIVE MEDICINE MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 30: NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD BILLION)
  • TABLE 31: NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 32: NORTH AMERICA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 33: NORTH AMERICA: REGENERATIVE MEDICINE, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 34: PRODUCTS WITH RMAT DESIGNATION (AS OF 2018)
  • TABLE 35: US: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 36: US: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 37: US: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 38: CANADA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 39: CANADA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 40: CANADA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 41: RESEARCH FUNDING EUROPEAN OVERVIEW
  • TABLE 42: EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD BILLION)
  • TABLE 43: EUROPE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 44: EUROPE: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 45: EUROPE: REGENERATIVE MEDICINE, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 46: UK: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 47: UK: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 48: UK: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 49: GERMANY: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 50: GERMANY: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 51: GERMANY: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 52: FRANCE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 53: FRANCE: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 54: FRANCE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 55: ROE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 56: ROE: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 57: ROE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 58: APAC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD BILLION)
  • TABLE 59: APAC: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 60: APAC: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 61: APAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 62: JAPAN: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 63: JAPAN: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 64: JAPAN: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 65: CHINA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 66: CHINA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 67: CHINA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 68: AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 69: AUSTRALIA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 70: AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 71: ROAPAC: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 72: ROAPAC: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 73: ROAPAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 74: ROW: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 75: ROW: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 76: ROW: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD BILLION)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: REGENERATIVE MEDICINE MARKET: BOTTOM-UP APPROACH
  • FIGURE 4: REGENERATIVE MEDICINE MARKET: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: REGENERATIVE MEDICINE MARKET, BY TYPE, 2019 VS. 2024 (USD BILLION)
  • FIGURE 7: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2019 VS. 2024 (USD BILLION)
  • FIGURE 8: REGENERATIVE MEDICINE MARKET, BY REGION, 2019 VS. 2024 (USD BILLION)
  • FIGURE 9: GROWING GOVERNMENT INVESTMENTS IN REGENERATIVE MEDICINE RESEARCH TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
  • FIGURE 10: MUSCULOSKELETAL DISORDERS TO DOMINATE THE REGENERATIVE MEDICINE MARKET IN 2019
  • FIGURE 11: COUNTRIES IN EUROPE TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 12: REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 13: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS SEGMENT TO DOMINATE THE MARKET IN 2018
  • FIGURE 14: ONCOLOGY SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE REGENERATIVE MEDICINE MARKET DURING THE FORECAST PERIOD
  • FIGURE 15: PREVALENCE OF DIABETES, BY REGION, 2015 VS. 2040
  • FIGURE 16: NORTH AMERICA TO WITNESS THE HIGHEST GROWTH IN THE REGENERATIVE MEDICINE MARKET DURING THE FORECAST PERIOD
  • FIGURE 17: INVESTMENT LEVELS QUADRUPLED DURING 2010-2016
  • FIGURE 18: NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
  • FIGURE 19: KEY DEVELOPMENTS IN THE REGENERATIVE MEDICINE MARKET
  • FIGURE 20: REGENERATIVE MEDICINE MARKET RANKING, BY KEY PLAYER, 2018
  • FIGURE 21: MNM DIVE-VENDOR COMPARISON MATRIX: REGENERATIVE MEDICINE MARKET
  • FIGURE 22: MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS: REGENERATIVE MEDICINE MARKET
  • FIGURE 23: NOVARTIS: COMPANY SNAPSHOT
  • FIGURE 24: VERICEL: COMPANY SNAPSHOT
  • FIGURE 25: INTEGRA LIFESCIENCES: COMPANY SNAPSHOT
  • FIGURE 26: MIMEDX GROUP: COMPANY SNAPSHOT
  • FIGURE 27: STRYKER : COMPANY SNAPSHOT
  • FIGURE 28: WRIGHT MEDICAL: COMPANY SNAPSHOT
  • FIGURE 29: OSIRIS THERAPEUTICS: COMPANY SNAPSHOT
Back to Top